Seido Capital
Montréal, Québec
Investment Thesis
Seido Capital invests in early-stage life sciences companies (pre-seed to Series B) across MedTech, Biotech, and AI in Health, with a North America primary focus. The fund operates with an exit-driven mindset, leveraging deep life-science expertise to identify locally disruptive technologies that can scale into global healthcare leaders, targeting 7-10x cash returns.
Focus Areas
Investment Stage
Pre-SeedSeries B+
Sectors
Investment Signals
GeographyNorth America
ProvincesQC, BC
Revenue Stagepre-revenue ok
Business ModelsB2B, deep-tech, hardware, IP-licensing
Sample Portfolio Companies
Henogen (acquired by Novasep/Thermo Fisher for €715M)
Ogeda (acquired by Astellas for €800M)
MaSTherCell (acquired by Catalent for €315M)
CluePoints (acquired by EQT at €700M+ - 33.2x MOIC, ~50% IRR)
Management Team
O
Olivier Bélenger
Cofounder & Managing Partner
T
Théo Risopoulos
Cofounder & GP
P
Patricia Escoffier
Principal
M
Michel Lussier
Partner
G
Gabrielle Girouard
PhD Analyst
What Makes Us Unique
Exit-driven mindset with deep life-science expertise. Start due diligence from the exit backwards. 50+ investments, 30+ exits, targeting 7-10x cash returns.
AUM & Sources
Est. US$140M
Assets under management (estimated)
Sources
No public sources found.
Raising from Canadian VCs?Get AI-matched to your top investors in seconds.
Find My Investors →Similar Funds
See incorrect information?
Help us keep this directory accurate and up to date.